Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...

I last covered Pfizer Inc. (PFE ... relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results.

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Pfizer PFE underwent analysis by 4 analysts in the last quarter ... the company may face hurdles in achieving optimal financial performance. Debt Management: Pfizer's debt-to-equity ratio is ...

Investing in oil company ConocoPhillips (NYSE: COP) was one of the failures during this time, having suffered $1.53 billion ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $152.57, a high ...

Organizations that develop sophisticated approaches to IP risk management can protect their exit potential and create ...

Should you flee the stock market? Not at all. Instead, to protect your portfolio, here are three things every investor should do.

Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to ...

Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025Company expects to complete analy ...